Literature DB >> 28873279

Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.

L V Srivaths1, Q C Zhang2, V R Byams2, J E Dietrich3, A H James4, P A Kouides5, R Kulkarni6.   

Abstract

INTRODUCTION: Due to lack of patient/health care provider awareness causing delayed diagnosis, the bleeding phenotype and provider interventions in adolescents with heavy menstrual bleeding (HMB) and bleeding disorders (BD) may be different when compared to adults. AIM: The aim of this study was to compare/characterize bleeding phenotype and provider interventions in postmenarchal adolescents < 18 years and premenopausal adults ≥ 18 years with HMB and BD.
METHODS: Patient demographics, BD, and provider interventions/therapy details for HMB were compared between both age groups enrolled in the Centers for Disease Control and Prevention (CDC) Female Universal Data Collection (UDC) surveillance project in United States hemophilia treatment centres. Cross-sectional descriptive analyses including frequency distributions, summary statistics, bivariate and logistic regression analyses were performed.
RESULTS: Of 269 females (79 adolescents; median age 16 years, interquartile range (IQR) = 2; 190 adults; median age 27 years, IQR = 13) evaluated, BD distribution was similar in both groups. Compared to adolescents, adults more often had family history of bleeding (Adjusted odds ratios [AOR] = 2.6, 1.3-5.6), delay in diagnosis (AOR = 2.5, 1.2-4.9), bleeding with dental procedures (AOR = 2.0, 1.0-4.0), gastrointestinal bleeding (AOR = 4.6, 1.0-21.9), anaemia (AOR = 2.7, 1.4-5.2), utilized desmopressin less often (AOR = 0.4, 0.2-0.8) and underwent gynaecologic procedure/surgery more frequently (AOR = 5.9, 1.3-27.3).
CONCLUSION: Bleeding phenotypes of adolescents and adults with HMB and BD were different with more frequent bleeding complications, anaemia, gynaecologic procedures/surgeries, less desmopressin use and more delay in diagnosing BD in adults. Longitudinal studies are needed to determine whether improved patient/provider awareness and education will translate to early diagnosis and timely management of BD/HMB in adolescents that may prevent/reduce future haematologic/gynaecologic complications.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  adolescents; bleeding disorder; bleeding phenotype; females; heavy menstrual bleeding; provider intervention

Mesh:

Substances:

Year:  2017        PMID: 28873279      PMCID: PMC5937715          DOI: 10.1111/hae.13330

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  17 in total

1.  Management of abnormal uterine bleeding in adolescents.

Authors:  Jeffrey P Wilkinson; Rezan A Kadir
Journal:  J Pediatr Adolesc Gynecol       Date:  2010-09-24       Impact factor: 1.814

Review 2.  Women and bleeding disorders.

Authors:  A H James
Journal:  Haemophilia       Date:  2010-07       Impact factor: 4.287

3.  Men with severe hemophilia in the United States: birth cohort analysis of a large national database.

Authors:  Marshall A Mazepa; Paul E Monahan; Judith R Baker; Brenda K Riske; J Michael Soucie
Journal:  Blood       Date:  2016-03-16       Impact factor: 22.113

Review 4.  Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding.

Authors:  Andrea S Lukes; Peter A Kouides; Keith A Moore
Journal:  Womens Health (Lond)       Date:  2011-03

5.  Oral Tranexamic Acid versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study.

Authors:  Lakshmi V Srivaths; Jennifer E Dietrich; Donald L Yee; Haleh Sangi-Haghpeykar; Donald Mahoney
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-12-29       Impact factor: 1.814

6.  Physical functioning in boys with hemophilia in the U.S.

Authors:  Paul E Monahan; Judith R Baker; Brenda Riske; J Michael Soucie
Journal:  Am J Prev Med       Date:  2011-12       Impact factor: 5.043

Review 7.  Gynecologic concerns in pubertal females with blood disorders.

Authors:  Lakshmi Venkateswaran; Jennifer E Dietrich
Journal:  J Pediatr Adolesc Gynecol       Date:  2012-10-23       Impact factor: 1.814

8.  Evaluation of bleeding disorders in women with menorrhagia: a survey of obstetrician-gynecologists.

Authors:  Vanessa R Byams; Britta L Anderson; Althea M Grant; Hani Atrash; Jay Schulkin
Journal:  Am J Obstet Gynecol       Date:  2012-07-16       Impact factor: 8.661

9.  Platelet functional defects in women with unexplained menorrhagia.

Authors:  C S Philipp; A Dilley; C H Miller; B Evatt; A Baranwal; R Schwartz; G Bachmann; P Saidi
Journal:  J Thromb Haemost       Date:  2003-03       Impact factor: 5.824

10.  Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States.

Authors:  A Kirtava; S Crudder; A Dilley; C Lally; B Evatt
Journal:  Haemophilia       Date:  2004-03       Impact factor: 4.287

View more
  3 in total

1.  Complex family planning and pediatric hematology oncology integrated clinic for young people with blood disorders and heavy or abnormal menstrual bleeding.

Authors:  Melody Y Hou; Sophia L Davis; Matthew D Ponzini; Machelle D Wilson; Anjali Pawar; Juliana Melo; Melissa J Chen
Journal:  Contraception       Date:  2022-01-11       Impact factor: 3.375

2.  The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding.

Authors:  Lakshmi Srivaths; Charles G Minard; Sarah H O'Brien; Allison P Wheeler; Eric Mullins; Mukta Sharma; Robert Sidonio; Shilpa Jain; Ayesha Zia; Margaret V Ragni; Roshni Kulkarni; Jennifer E Dietrich; Peter A Kouides
Journal:  Blood Adv       Date:  2020-07-14

3.  Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres.

Authors:  John Michael Soucie; Connie H Miller; Brandi Dupervil; Binh Le; Tyler W Buckner
Journal:  Haemophilia       Date:  2020-04-24       Impact factor: 4.263

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.